LtaS-IN-1 (compound 1771) 是一种高效的小分子脂磷壁酸 (LTA) 抑制剂，可抑制耐多药 (MDR) 大肠杆菌中脂磷壁酸 (LTA) 的合成，并可改变细胞壁的形态。LtaS-IN-1 单独使用抑制肠球菌的生长的 MIC 值范围从 0.5 μg/mL 到 64 μg/mL。LtaS-IN-1 与抗生素联合使用几乎可以完全抑制耐多药的大肠杆菌生长。

LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.

Solid

MIC: 0.5 μg/mL (strain E1630); 0.5 μg/mL (strain E1590)

LtaS-IN-1 (0-100 μM) inhibits strain E745 growth as a concentration-dependent manner. At the concentration 10 μM leads to an 60% reduction in the final OD600 for this strain. Meanwhile, LtaS-IN-1 does not affect E. faecium growth in control group.
LtaS-IN-1 is against Enterococcus spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 inhibits strain E1630 and E1590 with the MIC values of 0.5μg/mL.
LtaS-IN-1 (20 μM) combines with either ampicillin (20 μg/mL), gentamicin (10 μg/mL), linezolid (5 μg/mL), daptomycin (10 μg/mL+50 μg/mL calcium chloride) or vancomycin (20 μg/mL) can inhibit strains E7128 and E7130 growth by 97-100%, while LtaS-IN-1 alone only gives 73% (strain E7128) and 8% (strain E7130) of growth inhibition, respectively.
has not independently confirmed the

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Paganelli FL, et al. Lipoteichoic acid synthesis inhibition in combination with antibiotics abrogates growth of multidrug-resistant Enterococcus faecium.Int J Antimicrob Agents. 2017 Mar;49(3):355-363.

In Vitro: DMSO : 125 mg/mL (292.46 mM; Need ultrasonic)配制储备液